TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1546860

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 31
Study: 3885180

Group type: EXPERIMENTAL
Intervention: DTP-DT-DTP (Diphtheria-tetanus toxoids at 4 months, DTP at 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTP-DTP-DT (DTP at 4 months, Diphtheria-tetanus toxoids at 6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (DTP-DT-DTP and DTP-DTP-DT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTP-DT-DTP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTP-DT-DTP and DTP-DTP-DT
Number of subjects: 0
Study: 3370920

Group type: EXPERIMENTAL
Intervention: 100% O2 breathing
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 15% O2 breathing
Number of subjects: 11

Group type: COMPARATOR
Intervention: Air breathing
Number of subjects: 11
Study: 29431852

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 25815324

Group type: EXPERIMENTAL
Intervention: 10 mg lutein daily
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 20 mg lutein daily
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Combination of 10 mg lutein and 10 mg zeaxanthin daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 23918531

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy with pillar suturing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Adenotonsillectomy alone
Number of subjects: 24
Study: 21925062

Group type: EXPERIMENTAL
Intervention: MLC601 (NeuroAiD™), 4 capsules, 3 times a day for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, 4 capsules, 3 times a day for 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MLC601 (NeuroAiD™)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18283598

Group type: EXPERIMENTAL
Intervention: Levonorgestrel administered alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yuzpe regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrauterine device (IUD) with more than 300 mm2 of copper
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mifepristone (selective progesterone receptor modulator)
Number of subjects: 0
Study: 16457912

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline 1:200,000
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 45
Study: 12692872

Group type: EXPERIMENTAL
Intervention: Trachinaze (active device)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo device (control)
Number of subjects: 50
Study: 10784334

Group type: EXPERIMENTAL
Intervention: Intercondylar width (ICW) measurements
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Indices developed from ICW measurements
Number of subjects: 27
Study: 8794800

Group type: EXPERIMENTAL
Intervention: Dipyrone, 2.5 g
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nitroglycerin, 1 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: N‐butylscopolamine, 20 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tramadol, 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Indomethacin, 75 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 36
Study: 1616158

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (n = 20)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg succinylcholine (n = 10)
Number of subjects: 30
Study: 6379679

Group type: EXPERIMENTAL
Intervention: Sulindac (400 mg/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Naproxen (500 mg/day)
Number of subjects: 95
Study: 31069787

Group type: EXPERIMENTAL
Intervention: High UVA-protection factor sunscreen (SPF 15)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low UVA-protection factor sunscreen (SPF 15)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Discretionary sunscreen use
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonholiday group
Number of subjects: 20
Study: 30280641

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and etoposide
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo plus carboplatin and etoposide
Number of subjects: 403
Study: 26120052

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (intramuscular testosterone undecanoate for 40 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 40 weeks)
Number of subjects: 88
Study: 25070809

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 100 mg/d
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Modified Behavioral Self-Control Therapy (MBSCT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Brief Behavioral Compliance Enhancement Treatment (BBCET)
Number of subjects: 112
Study: 22585094

Group type: EXPERIMENTAL
Intervention: 20-week group treatment in addition to treatment as usual
Number of subjects: 71

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 71
Study: 20167847

Group type: EXPERIMENTAL
Intervention: AERAS-402 vaccine
Number of subjects: 0
Study: 18499959

Group type: COMPARATOR
Intervention: SHBG levels in hirsute girls (FG > 4)
Number of subjects: 252

Group type: COMPARATOR
Intervention: FT levels in hirsute girls (FG > 4)
Number of subjects: 252

Group type: COMPARATOR
Intervention: FT levels in hirsute subjects (FG > 4)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Correlation of FG with SHBG
Number of subjects: 252

Group type: COMPARATOR
Intervention: Correlation of FG with FT
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: SHBG values
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Slope of SHBG decrease
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: FT values
Number of subjects: 252
Study: 15827938

Group type: EXPERIMENTAL
Intervention: Deep heating (SWD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Superficial heating (hot packs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No heating
Number of subjects: 24
Study: 11216733

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 9462588

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (APAs)
Number of subjects: 6797

Group type: COMPARATOR
Intervention: Enalapril therapy
Number of subjects: 6797
Study: 8046423

Group type: COMPARATOR
Intervention: Quadrivalent vaccine (1 x 10(4) PFU each of D x RRV and RRV, followed 4 weeks later by 1 x 10(4) PFU each of DS1 x RRV and ST3 x RRV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quadrivalent vaccine (10(4) PFU of each component)
Number of subjects: 100

Group type: COMPARATOR
Intervention: M37 vaccine (10(4) PFU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Higher-titered quadrivalent vaccine (10(5) PFU of each component)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Higher-titered M37 vaccine (10(5) PFU)
Number of subjects: 100
Study: 2902873

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol
Number of subjects: 9
Study: 31868889

Group type: EXPERIMENTAL
Intervention: Therapy A - Bolus water drinking + physical counter‐manoeuvres (PCM)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Therapy B - Bolus water drinking + PCM + abdominal compression
Number of subjects: 37

Group type: COMPARATOR
Intervention: Single therapy (bolus water drinking)
Number of subjects: 37
Study: 31017476

Group type: EXPERIMENTAL
Intervention: TTM at 33 °C
Number of subjects: 171

Group type: COMPARATOR
Intervention: TTM at 36 °C
Number of subjects: 171
Study: 28387855

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 25840898

Group type: EXPERIMENTAL
Intervention: Nurse-led case management program on home exercise training
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 113
Study: 23660397

Group type: EXPERIMENTAL
Intervention: PCSO-524 (Lyprinol/Omega XL)
Number of subjects: 20
Study: 21542001

Group type: EXPERIMENTAL
Intervention: zoledronic acid (5 mg)
Number of subjects: 7736
Study: 19486788

Group type: EXPERIMENTAL
Intervention: 30 minutes of uninterrupted bed rest with music (soft and relaxing, new-age style, 50 to 60 dB, through a music pillow connected to an MP3 player)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 60 minutes of uninterrupted bed rest (control group)
Number of subjects: 58
Study: 17596468

Group type: EXPERIMENTAL
Intervention: Antenatal fetal surveillance in women with milder degrees of GDM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal timing and mode of delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fetal and pelvic imaging techniques
Number of subjects: 0
Study: 14969566

Group type: EXPERIMENTAL
Intervention: Pleconaril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11409665

Group type: EXPERIMENTAL
Intervention: Osteoporosis educational program (OEP), 3-hour duration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 9684701

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UH) (6,160 IU +/- 1,350 IU)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) (15 anti-Xa U/kg + 5 anti-Xa U/kg/h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 11
Study: 7849748

Group type: EXPERIMENTAL
Intervention: Tape
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Brace
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Elastic bandage
Number of subjects: 24
Study: 2904367

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1 (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1 (divided dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1 (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1 (divided dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1 (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1 (divided dose)
Number of subjects: 0
Study: 29727011

Group type: EXPERIMENTAL
Intervention: Tracheal intubation without neuromuscular blockade
Number of subjects: 248

Group type: COMPARATOR
Intervention: Tracheal intubation with neuromuscular blockade (rocuronium)
Number of subjects: 248
Study: 28536701

Group type: EXPERIMENTAL
Intervention: Cup-type respirator
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fold-type respirator without a valve
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fold-type respirator with a valve
Number of subjects: 24
Study: 26460536

Group type: EXPERIMENTAL
Intervention: Transdiagnostic CBT (TD‐CBT)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Disorder-specific CBT (DS‐CBT)
Number of subjects: 338
Study: 23880091

Group type: EXPERIMENTAL
Intervention: Integra(®)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cellonex™
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Split thickness skin graft (STSG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: All materials
Number of subjects: 10

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 10
Study: 21270326

Group type: EXPERIMENTAL
Intervention: iv recombinant hCG (1, 10, 25, 100, and 250 μg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: iv recombinant hCG (25 μg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal women (control group)
Number of subjects: 21
Study: 19481579

Group type: EXPERIMENTAL
Intervention: Deltoid injection of paliperidone palmitate (50, 75, or 100 mg eq.)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Gluteal injection of paliperidone palmitate (50, 75, or 100 mg eq.)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Deltoid and gluteal injections of paliperidone palmitate
Number of subjects: 252
Study: 16923411

Group type: EXPERIMENTAL
Intervention: High-dose folic acid multivitamin (5 mg folic acid, 50 mg vitamin B6, 1000 microg vitamin B12)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Low-dose folic acid multivitamin (0 mg folic acid, 1.4 mg vitamin B6, 2 microg vitamin B12)
Number of subjects: 4000
Study: 14970765

Group type: EXPERIMENTAL
Intervention: Active treatment using pulsed electromagnetic fields
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Active treatment for patients with anterior disk displacement without reduction
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Active treatment for patients with osteoarthritis
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Active treatment for patients with anterior disk displacement with reduction
Number of subjects: 76
Study: 11296449

Group type: EXPERIMENTAL
Intervention: ACD-CPR
Number of subjects: 64

Group type: COMPARATOR
Intervention: STD-CPR
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (ACD-CPR and STD-CPR)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Non-ROSC cases
Number of subjects: 64
Study: 9746450

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2330731

Group type: EXPERIMENTAL
Intervention: 1-day treatment with sulfamerazine/trimethoprim (Berlocombin)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7-day treatment with regular sulfamerazine/trimethoprim (Berlocombin)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7-day treatment with reduced sulfamerazine/trimethoprim (Berlocombin)
Number of subjects: 21
Study: 449434

Group type: EXPERIMENTAL
Intervention: Computerized medical record summary system
Number of subjects: 479

Group type: COMPARATOR
Intervention: Traditional medical record
Number of subjects: 479
Study: 31012742

Group type: EXPERIMENTAL
Intervention: Test of Self‐Conscious Affect‐3 (TOSCA‐3)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Personal Feelings Questionnaire‐2 (PFQ‐2)
Number of subjects: 138
Study: 31486729

Group type: EXPERIMENTAL
Intervention: Team-based ACP using the Serious Illness Care Program (SICP)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Clinician-focused ACP using the Serious Illness Care Program (SICP)
Number of subjects: 1260
Study: 28626257

Group type: EXPERIMENTAL
Intervention: Grasping exercises in the Hand Incubator device for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 25776739

Group type: EXPERIMENTAL
Intervention: Cross-linked polyethylene (XLK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional polyethylene (GVF)
Number of subjects: 0
Study: 24585363

Group type: EXPERIMENTAL
Intervention: Arthroscopic capsular release including release of the rotator interval and anterior and inferior capsule (Group I, n = 37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Arthroscopic capsular release extended to the posterior capsule (Group II, n = 38)
Number of subjects: 75
Study: 22215856

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 20141630

Group type: EXPERIMENTAL
Intervention: Cryotherapy using liquid nitrogen for a maximum of 4 treatments (2-3 weeks apart)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Salicylic acid (50%) self-treatment for a maximum of 8 weeks
Number of subjects: 266
Study: 18043528

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 31
Study: 16086929

Group type: EXPERIMENTAL
Intervention: Walking (hours per day)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Various treatment arms
Number of subjects: 874
Study: 12171841

Group type: EXPERIMENTAL
Intervention: CFC‐FP 500 microg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CFC‐FP 1000 microg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HFA‐FP 500 microg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HFA‐FP 1000 microg/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10354026

Group type: EXPERIMENTAL
Intervention: Mometasone furoate on Sunday, Tuesday and Thursday (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mometasone furoate on Saturday and Sunday (group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No further corticosteroid treatment (group C)
Number of subjects: 120
Study: 8965290

Group type: EXPERIMENTAL
Intervention: Fitness program
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: School and home nutrition
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Home nutrition
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1147
Study: 1354687

Group type: EXPERIMENTAL
Intervention: Tocopherol (dl-alpha-tocopherol nicotinate, 200 mg, tid)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tocopherol (200 mg, tid)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tocopherol (in vitro, 0.1 to 3.0 mM)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tocopherol (0.1 mM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6499511

Group type: EXPERIMENTAL
Intervention: 200 mg meptazinol every 3 to 6 hours as required for 72 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31022368

Group type: EXPERIMENTAL
Intervention: Dietary intake assessed using three 24-hour recalls and scored for HEI-2010
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Dietary intake assessed using three 24-hour recalls and scored for AHEI-P
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Micronutrient intake assessment
Number of subjects: 170
Study: 29042063

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (10 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (5 mL)
Number of subjects: 30
Study: 25833706

Group type: EXPERIMENTAL
Intervention: Perfect adherence (100%)
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Moderately high adherence (75-99%)
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Moderately low adherence (50-74%)
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Low adherence (<50%)
Number of subjects: 988
Study: 24211840

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10Hz) over the left DLPFC, 110% motor threshold, 20 trains, 10s duration per train, 30s inter-train interval, 21 sessions, total 42,000 pulses
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham rTMS (placebo stimulation)
Number of subjects: 35
Study: 23050557

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CJLP133 (0.5 × 10^10 CFU, twice a day for 12 weeks)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 19066606

Group type: EXPERIMENTAL
Intervention: 8-oxo-dG levels in tumor tissue
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Epithelial nuclear and stromal staining in normal mucosa and tumor
Number of subjects: 143

Group type: COMPARATOR
Intervention: Nuclear staining levels in tumor tissue and matched normal mucosa
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 8-oxo-dG levels with local disease spread
Number of subjects: 143

Group type: COMPARATOR
Intervention: Normal control cells in tissue from cancer patients with high levels of 8-oxo-dG
Number of subjects: 143
Study: 17469752

Group type: EXPERIMENTAL
Intervention: Acrysof Natural IOL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard Acrysof IOL (Control)
Number of subjects: 30
Study: 15234224

Group type: EXPERIMENTAL
Intervention: Markov surgical decision analysis
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard decision-making
Number of subjects: 206
Study: 12361896

Group type: EXPERIMENTAL
Intervention: Alfuzosin SR
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 9545151

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study: 7715622

Group type: EXPERIMENTAL
Intervention: Exercise training group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Natural history (control) group
Number of subjects: 16
Study: 2236714

Group type: EXPERIMENTAL
Intervention: Barbotage with isobaric bupivacaine 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Barbotage with hyperbaric bupivacaine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: No barbotage with isobaric bupivacaine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: No barbotage with hyperbaric bupivacaine 0.5%
Number of subjects: 60
Study: 35391

Group type: EXPERIMENTAL
Intervention: Quickly dried and exposed to room air (group B)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Wrapped with two towels (group D)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Not dried and exposed wet to room air (group A)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Warmed under the radiant heater (group F)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Wrapped with one sterile sheet (group C)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Placed under the radiant heater (group E)
Number of subjects: 53
Study: 31350545

Group type: EXPERIMENTAL
Intervention: Noncooperative-group-sponsored trials
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cooperative group trials
Number of subjects: 147
Study: 31066177

Group type: EXPERIMENTAL
Intervention: Intensive treatment (<120 mm Hg)
Number of subjects: 11784

Group type: COMPARATOR
Intervention: Standard treatment (<140 mm Hg)
Number of subjects: 11784
Study: 27584578

Group type: EXPERIMENTAL
Intervention: Arginine deprivation with ADI-PEG20 (36.8 mg/m2, weekly intramuscular) plus best supportive care (BSC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 68